304 related articles for article (PubMed ID: 29617862)
1. Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing.
Ouchi Y; Patil A; Tamura Y; Nishimasu H; Negishi A; Paul SK; Takemura N; Satoh T; Kimura Y; Kurachi M; Nureki O; Nakai K; Kiyono H; Uematsu S
Int Immunol; 2018 Apr; 30(4):141-154. PubMed ID: 29617862
[TBL] [Abstract][Full Text] [Related]
2. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
3. A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen.
Bianchi V; Bulek A; Fuller A; Lloyd A; Attaf M; Rizkallah PJ; Dolton G; Sewell AK; Cole DK
J Biol Chem; 2016 Apr; 291(17):8951-9. PubMed ID: 26917722
[TBL] [Abstract][Full Text] [Related]
4. Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence.
Gannon PO; Wieckowski S; Baumgaertner P; Hebeisen M; Allard M; Speiser DE; Rufer N
J Immunol; 2015 Jul; 195(1):356-66. PubMed ID: 26002978
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
Rupp LJ; Schumann K; Roybal KT; Gate RE; Ye CJ; Lim WA; Marson A
Sci Rep; 2017 Apr; 7(1):737. PubMed ID: 28389661
[TBL] [Abstract][Full Text] [Related]
6. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
Bullock TN; Mullins DW; Colella TA; Engelhard VH
J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
[TBL] [Abstract][Full Text] [Related]
7. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
Kondo K; Fujiki F; Nakajima H; Yatsukawa E; Morimoto S; Tatsumi N; Nishida S; Nakata J; Oka Y; Tsuboi A; Hosen N; Oji Y; Sugiyama H
J Immunother; 2016 Apr; 39(3):127-39. PubMed ID: 26938946
[TBL] [Abstract][Full Text] [Related]
8. High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence.
Carretero-Iglesia L; Couturaud B; Baumgaertner P; Schmidt J; Maby-El Hajjami H; Speiser DE; Hebeisen M; Rufer N
Front Immunol; 2019; 10():3016. PubMed ID: 31969886
[TBL] [Abstract][Full Text] [Related]
9. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
10. Generation of CD8(+) T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy.
Höfflin S; Prommersberger S; Uslu U; Schuler G; Schmidt CW; Lennerz V; Dörrie J; Schaft N
Cancer Biol Ther; 2015; 16(9):1323-31. PubMed ID: 26178065
[TBL] [Abstract][Full Text] [Related]
11. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.
Pouw N; Treffers-Westerlaken E; Kraan J; Wittink F; ten Hagen T; Verweij J; Debets R
Cancer Immunol Immunother; 2010 Jun; 59(6):921-31. PubMed ID: 20101507
[TBL] [Abstract][Full Text] [Related]
12. Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma.
Uslu U; Schuler G; Dörrie J; Schaft N
Exp Dermatol; 2016 Nov; 25(11):872-879. PubMed ID: 27246630
[TBL] [Abstract][Full Text] [Related]
13. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
14. Optimizing T-cell receptor avidity with somatic hypermutation.
Bassan D; Gozlan YM; Sharbi-Yunger A; Tzehoval E; Eisenbach L
Int J Cancer; 2019 Nov; 145(10):2816-2826. PubMed ID: 31381134
[TBL] [Abstract][Full Text] [Related]
15. Administration of sulfosuccinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate conjugated GP100(25-33) peptide-coupled spleen cells effectively mounts antigen-specific immune response against mouse melanoma.
Chang X; Xia CQ
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):46-52. PubMed ID: 26545782
[TBL] [Abstract][Full Text] [Related]
16. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
[TBL] [Abstract][Full Text] [Related]
17. T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.
Circosta P; Granziero L; Follenzi A; Vigna E; Stella S; Vallario A; Elia AR; Gammaitoni L; Vitaggio K; Orso F; Geuna M; Sangiolo D; Todorovic M; Giachino C; Cignetti A
Hum Gene Ther; 2009 Dec; 20(12):1576-88. PubMed ID: 19678763
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8(+) T-cell Response and Protects Mice from Melanoma.
Qiu Z; Huang H; Grenier JM; Perez OA; Smilowitz HM; Adler B; Khanna KM
Cancer Immunol Res; 2015 May; 3(5):536-46. PubMed ID: 25633711
[TBL] [Abstract][Full Text] [Related]
19. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
[TBL] [Abstract][Full Text] [Related]
20. The Antitumor Effects of Vaccine-Activated CD8
Wu S; Zhu W; Peng Y; Wang L; Hong Y; Huang L; Dong D; Xie J; Merchen T; Kruse E; Guo ZS; Bartlett D; Fu N; He Y
Cancer Immunol Res; 2017 Oct; 5(10):908-919. PubMed ID: 28851693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
